Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gemzar Narrow Progression-Free Survival Benefit To Test Oncology Panel's Efficacy Bar

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's Oncologic Drugs Advisory Committee will review Lilly's gemcitabine for treatment of advanced ovarian cancer March 13.

You may also be interested in...



Gemzar Ovarian Cancer Data Not Sufficient For Approval In Recurrent Disease, Committee Says

While FDA advisory committee accepts that Lilly’s Gemzar plus carboplatin may have had an effect on progression-free survival in ovarian cancer, poor study design and lack of overall survival benefit sink approval recommendation.

Gemzar Ovarian Cancer Data Not Sufficient For Approval In Recurrent Disease, Committee Says

While FDA advisory committee accepts that Lilly’s Gemzar plus carboplatin may have had an effect on progression-free survival in ovarian cancer, poor study design and lack of overall survival benefit sink approval recommendation.

Tarceva Survival Advantage In Pancreatic Cancer Not "Clinically Meaningful," FDA Says

The agency's briefing documents for Tarceva's Oncologic Drugs Advisory Committee review raise concerns about rates of serious adverse events and treatment-related fatalities.

Topics

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel